Newsroom
New START site to be established in collaboration with Baptist Health Herbert Wertheim Cancer Institute will bring novel oncology therapies closer to patients across South Florida Baptist Health South Florida and The START Center for Cancer Research, the largest global network of fully dedicated, early-phase oncology clinical trial sites, today
Strengthening clinical research capabilities in one of the nation’s most densely populated and high-opportunity oncology markets The START Center for Cancer Research (“START”), the world’s largest community-based network of clinical trial sites specializing in early-phase oncology trials, today announced the appointment of Neel Belani, MD, MBA, as Clinical Investigator at
Dr. Al Mutar brings deep expertise in gastrointestinal oncology and early-phase clinical trials and will help to expand access to innovative therapies across North Texas The START Center for Cancer Research (“START”), the world’s largest community-based network of clinical trial sites specializing in early-phase oncology trials, today announced the appointment
Partnership will enhance physician awareness of START’s portfolio of trials, streamline referrals, and support patient access to early-phase oncology research The START Center for Cancer Research (“START”), the world’s largest community-based network of clinical trial sites specializing in early-phase oncology trials, today announced a strategic partnership with Trialing, a platform
Dr. Hafez will lead the new early-phase research site at Los Angeles Cancer Network, one of the nation’s largest and most diverse community-based oncology practices The START Center for Cancer Research (“START”), the world’s largest community-based network specializing in early-phase oncology trials, today announced the appointment of Navid Hafez, MD,
The first START site in New York launches new strategic partnership to provide cutting-edge cancer research Northwell Health and The START Center for Cancer Research held a ceremonial ribbon-cutting to unveil Northwell-START New York-Long Island, which reflects a $5.7 million investment for a 10,000-square foot, state-of-the-art early-phase cancer clinical trial
